ATE432708T1 - Therapeutische anwendungen von beta-casein a2 und nahrungsergänzung mit beta-casein a2 - Google Patents

Therapeutische anwendungen von beta-casein a2 und nahrungsergänzung mit beta-casein a2

Info

Publication number
ATE432708T1
ATE432708T1 AT03770160T AT03770160T ATE432708T1 AT E432708 T1 ATE432708 T1 AT E432708T1 AT 03770160 T AT03770160 T AT 03770160T AT 03770160 T AT03770160 T AT 03770160T AT E432708 T1 ATE432708 T1 AT E432708T1
Authority
AT
Austria
Prior art keywords
casein
beta
sup
cholesterol
density lipoprotein
Prior art date
Application number
AT03770160T
Other languages
English (en)
Inventor
Julie Hazel Campbell
Kristy Ann Tailford
Ulrike Hf Mclachlan
Corran Norman Stuart Mclachlan
Original Assignee
A2 Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Corp Ltd filed Critical A2 Corp Ltd
Application granted granted Critical
Publication of ATE432708T1 publication Critical patent/ATE432708T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03770160T 2002-10-04 2003-10-03 Therapeutische anwendungen von beta-casein a2 und nahrungsergänzung mit beta-casein a2 ATE432708T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ52195502 2002-10-04
PCT/NZ2003/000222 WO2004030690A1 (en) 2002-10-04 2003-10-03 THERAPEUTIC USES OF β-CASEIN A2 AND DIETARY SUPPLEMENT CONTAINING β-CASEIN A2

Publications (1)

Publication Number Publication Date
ATE432708T1 true ATE432708T1 (de) 2009-06-15

Family

ID=32065083

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03770160T ATE432708T1 (de) 2002-10-04 2003-10-03 Therapeutische anwendungen von beta-casein a2 und nahrungsergänzung mit beta-casein a2

Country Status (13)

Country Link
US (1) US20060280802A1 (de)
EP (1) EP1562629B1 (de)
JP (1) JP4870355B2 (de)
KR (1) KR101065099B1 (de)
CN (1) CN100377740C (de)
AT (1) ATE432708T1 (de)
AU (1) AU2003278625A1 (de)
CA (1) CA2500530C (de)
DE (1) DE60327880D1 (de)
DK (1) DK1562629T3 (de)
ES (1) ES2329031T3 (de)
NZ (1) NZ538904A (de)
WO (1) WO2004030690A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130020939A (ko) * 2002-07-03 2013-03-04 에이2 코포레이션 리미티드 우유의 지방산 조성을 변경시키는 방법
CN101410131B (zh) 2006-06-09 2012-09-12 森永乳业株式会社 脂质代谢改善剂
EA018295B1 (ru) * 2008-12-09 2013-06-28 Унилевер Н.В. Замороженные аэрированные кондитерские изделия и способы их получения
ES2742306T3 (es) * 2013-05-31 2020-02-13 A2 Milk Co Ltd Composición que comprende beta-caseína A2 para su uso en la prevención de la inflamación del intestino
SG11201510707YA (en) * 2013-07-12 2016-01-28 A2 Milk Company Ltd Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
RU2698794C2 (ru) * 2013-08-23 2019-08-30 Зэ А2 Милк Компани Лимитед Бета-казеин а2 и уровень глюкозы в крови
CA2826315A1 (en) 2013-09-06 2015-03-06 Mattawa Industrial Services Inc. Elevation conveyance system and method
EP3297643A4 (de) * 2015-05-22 2019-02-06 The A2 Milk Company Limited Beta-casein-a2 und antioxidative kapazität
WO2018063008A1 (en) * 2016-09-30 2018-04-05 The A2 Milk Company Limited Beta-caseins and gut microbiota
US12344918B2 (en) 2023-07-12 2025-07-01 Ati Properties Llc Titanium alloys
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06165655A (ja) * 1992-06-26 1994-06-14 Meiji Milk Prod Co Ltd コレステロール低減用組成物
CA2204245C (en) * 1994-11-04 2008-07-22 Robert Bartlett Elliott Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
CA2217820C (en) * 1995-05-16 2011-03-01 Corran Norman Stuart Mclachlan Milk and milk products for preventing or treating heart disease
US6570060B2 (en) * 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
AU771754B2 (en) * 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk

Also Published As

Publication number Publication date
WO2004030690A1 (en) 2004-04-15
JP4870355B2 (ja) 2012-02-08
CA2500530A1 (en) 2004-04-15
ES2329031T3 (es) 2009-11-20
US20060280802A1 (en) 2006-12-14
NZ538904A (en) 2009-04-30
CN1720062A (zh) 2006-01-11
DK1562629T3 (da) 2009-10-12
KR20050087785A (ko) 2005-08-31
JP2006501299A (ja) 2006-01-12
CN100377740C (zh) 2008-04-02
EP1562629B1 (de) 2009-06-03
DE60327880D1 (de) 2009-07-16
AU2003278625A1 (en) 2004-04-23
EP1562629A4 (de) 2007-08-29
KR101065099B1 (ko) 2011-09-16
CA2500530C (en) 2013-01-08
HK1082910A1 (en) 2006-06-23
EP1562629A1 (de) 2005-08-17

Similar Documents

Publication Publication Date Title
Suri et al. DASH dietary pattern: a treatment for non-communicable diseases
UA88633C2 (ru) Структурированная композиция на основе липидов, способ ее изготовления и способ снижения атерогенного риска человека
ATE432708T1 (de) Therapeutische anwendungen von beta-casein a2 und nahrungsergänzung mit beta-casein a2
EE03747B1 (et) Stanooli kompositsioon ja selle kasutamine
WO2002015719A3 (en) Nutritional composition
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ATE514345T1 (de) Zusammensetzung zur senkung des blutcholesterolspiegels
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
BR9707713A (pt) Composição e sua utilização como umm suplemento alimentar ou para reduzir o nìvel plasmático de lipìdios.
Jemil et al. Hypolipidemic, antiobesity and cardioprotective effects of sardinelle meat flour and its hydrolysates in high-fat and fructose diet fed Wistar rats
WO2004016101A3 (en) Compositions comprising dietary fat complexer and methods for their use
Rusu et al. Medical nutrition therapy in non-alcoholic fatty liver disease–a review of literature
Santanam et al. Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis
WO2001032160A3 (en) Modification of cholesterol concentrations with citrus phytochemicals
DE602004004905D1 (de) Mit calcium angereicherte kleinkindernährmittel auf sojabasis
Prasad et al. Evidence for multiple condensing enzymes in rat hepatic microsomes catalyzing the condensation of saturated, monounsaturated, and polyunsaturated acyl coenzyme A.
Cater Plant stanol ester: review of cholesterol‐lowering efficacy and implications for coronary heart disease risk reduction
DE502004008949D1 (de) Physiologisch aktive zusammensetzung auf phosphatidylserin-basis
IL160533A0 (en) Methods of screening molecules that are used to prevent cardiovascular diseases
DK1611794T3 (da) Margarinelignende fødevaresammensætning med reduceret fedtindhold
Posthauer Do patients with pressure ulcers benefit from oral zinc supplementation?
Mastroianni et al. Increased plasma HDL-cholesterol and apo AI in breast cancer patients undergoing adjuvant tamoxifen therapy
Kara et al. Improving performance through nutrition: muscle recovery strategies
Braith Does resistance exercise training reduce the risk of cardiovascular disease?
Meletis Dietary and lifestyle interventions for a healthy heart

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties